Respiratory Assist Devices CPAP-BiPAP - Health Plan of Nevada

. Sleep oximetry demonstrates oxygen saturation less-than-or-equal-to 88% for
at least five continuous minutes, done while breathing the individual’s usual
FIO2, or
c. Maximal inspiratory pressure for progressive neuromuscular disease is, less
than 60 cm H20 or forced vital capacity is less than 50% predicted, and
1. Chronic obstructive pulmonary disease (COPD) does not contribute
significantly to the individual’s pulmonary limitation.
2. If the above criteria are met, either an E0470 or E0471 device will be
covered for individuals within this group of conditions for the first three
months of NPPRA therapy.
B. Severe COPD
1. An arterial blood gas PaCO2, was done while individual was awake and breathing
the individual’s usual FIO2, is greater-than-or-equal-to 52 mm Hg; and
2. Sleep oximetry demonstrates oxygen saturation less-than-or-equal-to 88% for at
least five continuous minutes, done while breathing oxygen at 2 liter per minute or
the individual’s usual FIO2, whichever is higher; and
3. Obstructive Sleep Apnea (OSA) (and treatment with CPAP) has been considered
and ruled out prior to initiating therapy.
4. If all of the above criteria for individuals with COPD are met, an E0470 device
will be covered for the first three months of NPPRA therapy.
5. An E0471 device will not be covered for an individual with COPD during the first
two months, because therapy with an E0470 device with proper adjustments of the
device’s setting and individual accommodation to its use will usually result in
sufficient improvement without the need of a back-up rate.
C. Central Sleep Apnea (CSA) or Complex Sleep Apnea (CompSA) (apnea not due to airway
obstruction)
1. Prior to initiating therapy, a complete facility-based, attended polysonigraph
(PSG) must be performed documenting the following:
a. The diagnosis of CSA or CompSA (see definitions in Appendices section);
b. The ruling out of CPAP as effective therapy if either CSA or OSA is a
component of the initially observed sleep-associated hypoventilation; and
c. Significant improvement of the sleep-associated hypoventilation with the use
of an E0470 or E0471 device on the settings that will be prescribed for initial
use at home, while breathing the individual’s usual FIO2.
2. If all above criteria are met, either an E0470 or E0471 device (based upon the
judgment of the treating physician) will be covered for individuals with
documented CSA or CompSA for the first three months of NPPRA therapy.
Obstructive Sleep Apnea (OSA)
1. A complete facility-based, attended polysomnogram, has established the diagnosis
of obstructive sleep apnea according to the following criteria:
a. The Apnea-Hypopnea Index (AHI) is greater-than-or-equal-to15 events per
hour; or
Respiratory Assist Devices_CPAP-BiPAP Page 2 of 9